Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05116189
Title Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Age Groups: adult | senior
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | AUS

No variant requirements are available.